May 15 2010
EvoLife Laboratories, a world leader in the development of products for skin, oral, nail, hair, hygiene care specifically designed for cancer patients undergoing chemotherapy and radiotherapy, successfully launched its products in the USA. EvoLife Laboratories is present at the annual Oncology Nursing Society (ONS) Congress 2010 in San Diego and utilizes this opportunity to further engage with nurses and caregivers. EvoLife Laboratories has been continuously working with the nursing community all around the EU and Asia.
"MY NEW LIFE" Trial Program
Quality of life affected by cancer treatment side-effects among patients and lack of products to address these problems continue to be serious challenges for patients and caregivers involved with treatment. The quality of life improvement among cancer patients is becoming a priority for key stakeholders, including the patient's family, who are involved with cancer treatment, particularly efforts to improve their daily life and increase ability to undergo and stay on their treatment regimen. As part of the "MY NEW LIFE" trial program, EvoLife will provide nurses appropriate products for their use in order to assist patients. EvoLife products "contain a unique blend of natural minerals which have shown to assist patients by providing ultimate hydration and protection." They are the first and only products of their kind that are effective, uniquely designed with the needs of cancer patients in mind and well tested.
Industry Feedback
The niche market has deepened due to the increasing use of targeted therapies. "Some chemo causes terrible rashes and acne on the face and neck," says Ann Richards, supervisor at the Mayo Clinic Erickson Hair and Skin Care Center. "Patients don't know what to do about it."
Carrie Mellage, director of consumer products for Kline & Company market research, noted that with all the changes cancer patients must deal with, adjusting their personal-care regimen may not be a top priority. But she does see growth potential. "There is a definite opportunity here," Mellage said. "EvoLife appears to be a relevant and empathetic brand and could certainly be successful in its own right." EvoLife already has plans to extend its portfolio, with sunscreen and toothpaste innovations in the pipeline – The Rose Sheet Vol. 31, No. 17, April 2010.
Additionally, caregivers have reported positive results. Johanna, (Nurse from London, UK) writes, "EvoSkin has been very effective. I have been giving this to patients receiving head and neck radiation, and they tend to suffer from the worst skin reactions. The patients prefer it to standard aqueous we usually give them at the beginning of treatment. The EvoDeo, an alcohol/metal free deodorant spray, is a big relief for breast cancer patients. Thank you for your ongoing support and help."
Innovative urine test could improve pancreatic cancer survival rates